C. Francis

发表

Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight

A. Khorana, A. Sahni, O. Altland, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides.

H. Scheraga, C. Francis, L. Hanna, 1984, Biochemistry.

Low‐intensity ultrasound increases endothelial cell nitric oxide synthase activity and nitric oxide synthesis

O. Altland, C. Francis, D. Dalecki, 2004, Journal of thrombosis and haemostasis : JTH.

Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

D. Rubens, A. Khorana, C. Francis, 2017, Thrombosis research.

Magnetic resonance imaging of blood and clots in vitro.

C. Francis, R. Bryant, V. Marder, 1990, Investigative radiology.

Magnetic Resonance Imaging of Deep Vein Thrombi Correlates with Response to Thrombolytic Therapy

C. Francis, S. Totterman, C. Francis, 1995, Thrombosis and Haemostasis.

Ultrasound Improves Tissue Perfusion in Ischemic Tissue through a Nitric Oxide Dependent Mechanism

C. Francis, R. Baggs, V. Suchkova, 2002, Thrombosis and Haemostasis.

March 22 Highlight and Commentary

C. Francis, 2005, Neurology.

Ultrasound energy improves myocardial perfusion in the presence of coronary occlusion.

C. Francis, S. Kobal, Huai Luo, 2004, Journal of the American College of Cardiology.

Effect of 40-kHz ultrasound on acute thrombotic ischemia in a rabbit femoral artery thrombosis model: enhancement of thrombolysis and improvement in capillary muscle perfusion.

C. Francis, R. Baggs, V. Suchkova, 2000, Circulation.

Ultrasound‐Enhanced Thrombolysis

C. Francis, 2001, Echocardiography.

Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future.

A. Khorana, C. Francis, 2018, Thrombosis research.

Cancer-associated thrombosis.

C. Francis, G. Connolly, 2013, Hematology. American Society of Hematology. Education Program.

MODULATION OF CELL PROLIFERATION ON FIBRIN 1803 from the peptide and DNA Sequence

C. Francis, L. A. Sporn, L. Bunce, 2002 .

Cell proliferation on fibrin: modulation by fibrinopeptide cleavage.

C. Francis, L. A. Sporn, L. Bunce, 1995, Blood.

Consultations on patients with venous or arterial diseases.

C. Francis, W. Hiatt, M. R. Jackson, 2003, Hematology. American Society of Hematology. Education Program.

Vascular Imaging in the Asymptomatic High‐risk Cancer Population

D. Rubens, A. Khorana, C. Francis, 2021, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

A. Khorana, C. Francis, G. Lyman, 2016, The oncologist.

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study

C. Francis, S. Goldhaber, T. Ortel, 2015, Journal of thrombosis and haemostasis : JTH.

Platelets and cancer-associated thrombosis.

C. Francis, R. Phipps, G. Connolly, 2014, Seminars in oncology.

A computerized prompt for thromboprophylaxis in hospitalized cancer patients.

A. Khorana, C. Francis, T. Baird, 2010, Thrombosis research.

Venous Thromboembolism andAnticoagulation

A. Khorana, C. Francis, M. Rao, 2008 .

Relation of Factor V Leiden Genotype to Risk for Acute Deep Venous Thrombosis after Joint Replacement Surgery

C. Francis, M. Crowther, Jeffrey S. Ginsberg, 1998, Annals of Internal Medicine.

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double‐blind study

C. Colwell, C. Francis, S. Berkowitz, 2003, Journal of thrombosis and haemostasis : JTH.

Endothelial Cell Activation by IL-1β in the Presence of Fibrinogen Requires αVβ3

A. Sahni, C. Francis, S. Sahni, 2005 .

Fibrin induces release of von Willebrand factor from endothelial cells.

C. Francis, D. Wagner, J. Ribes, 1987, The Journal of clinical investigation.

Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury.

C. Francis, V. Marder, D. Penney, 1994, Thrombosis research.

Effects of lipids and lipid‐lowering therapy on hemostatic factors in patients with myocardial infarction

A. Moss, C. Francis, W. Zareba, 2004, Journal of thrombosis and haemostasis : JTH.

Foxp3 Regulates Megakaryopoiesis and Platelet Function

C. Francis, A. Koniski, J. Palis, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Nuclear Factor κB Protects against Host Cell Apoptosis during Rickettsia rickettsii Infection by Inhibiting Activation of Apical and Effector Caspases and Maintaining Mitochondrial Integrity

C. Francis, S. Joshi, S. Sahni, 2003, Infection and Immunity.

Disseminated intravascular coagulation and status epilepticus

C. Francis, C. Commichau, A. Felcher, 1998, Neurology.

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

C. Francis, J. Fiessinger, M. Huisman, 2005, JAMA.

Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis

C. Francis, J. Fiessinger, M. Huisman, 2005 .

Rochester Center for Biomedical Ultrasound 2001 Annual Report Research Biophysical Bases of Pulsed Ultrasound Bioeffects (nci) and Ultrasound-induced Hyperthermic Teratogenicity (nichhd) 4 a K-space Method for Large-scale Models of Wave Propagation in Tissue 5 Time-shift Estimation and Focusing thro

Morton W. Miller, T. D. Mast, J. Ophir, 2022 .

Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993)

M. Blombäck, C. Francis, B. Dahlbäck, 1994, Thrombosis and Haemostasis.

Heparin-induced thrombocytopenia.

C. Francis, K. Kaplan, Charles W. Francis, 1999, Blood reviews.

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

G. Raskob, C. Francis, M. Clements, 2009, The Journal of arthroplasty.

Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.

C. Francis, W. Hood, V. Marder, 1985, Circulation.

Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin.

C. Francis, Charles, J. Ribes, 1990, Blood.

Fibrinogen binding potentiates FGF‐2 but not VEGF induced expression of u‐PA, u‐PAR, and PAI‐1 in endothelial cells

A. Sahni, C. Francis, P. Simpson‐Haidaris, 2004, Journal of thrombosis and haemostasis : JTH.

The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects

C. Francis, D. Springer, G. Lehmann, 2007, PPAR research.

Characterization of ultrasound-potentiated fibrinolysis in vitro

C. Francis, E. Carstensen, A. Blinc, 1993 .

Flow through clots determines the rate and pattern of fibrinolysis.

C. Francis, S. Kennedy, R. Bryant, 1994, Thrombosis and haemostasis.

Characterization of ultrasound-potentiated fibrinolysis in vitro.

C. Francis, E. Carstensen, A. Blinc, 1993, Blood.

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

C. Colwell, C. Francis, G. Paiement, 2003, The New England journal of medicine.

Ultrasound enhancement of thrombolysis and reperfusion in vitro.

C. Francis, V. Marder, R. Meltzer, 1993, Journal of the American College of Cardiology.

A Soluble Fibrin Standard: Comparable Dose-response with Immunologic and Functional Assays

C. Francis, V. Marder, B. McCarron, 1999, Thrombosis and Haemostasis.

Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.

J. T. Horan, C. Francis, Charles W. Francis, 2001, Seminars in thrombosis and hemostasis.

New Thrombolytic Drugs

C. Francis, 2001 .

Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.

C. Francis, V. Marder, G. Barlow, 1980, The Journal of clinical investigation.

Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.

C. Francis, V. Marder, D. Connaghan, 1986, Circulation.

Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.

C. Francis, V. Marder, R. Rothbard, 1986, Annals of internal medicine.

MYOCARDIAL INFARCTION Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction

C. Francis, V. Marder, D. Connaghan, 2022 .

An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.

C. Francis, V. Marder, 1984, Progress in hemostasis and thrombosis.

A Molecular Model of Plasmic Degradation of Crosslinked Fibrin

C. Francis, V. Marder, 1982, Seminars in thrombosis and hemostasis.

Plasminogen activator inhibitor-1 levels and polymorphisms.

C. Francis, 2002, Archives of pathology & laboratory medicine.

Chapter 26 – Antithrombotic Agents

C. Francis, Charles W. Francis, 2007 .

Anticardiolipin Antibodies and Recurrent Coronary Events

A. Moss, C. Francis, W. Zareba, 2000 .

Anticardiolipin Antibodies and Recurrent Coronary Events: A Prospective Study of 1150 Patients

A. Moss, C. Francis, W. Zareba, 2000, Circulation.

A response to – There's madness in their methods

G. Guyatt, E. Akl, C. Francis, 2013, Journal of thrombosis and haemostasis : JTH.

Prevention of venous thromboembolism in hospitalized patients with cancer.

C. Francis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylaxis for Thromboembolism in Hospitalized Medical Patients

C. Francis, 2007 .

Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

G. Guyatt, E. Akl, C. Francis, 2012, Chest.

Approach to pancytopenia: Diagnostic algorithm for clinical hematologists.

C. Francis, C. Takemoto, S. Hashmi, 2018, Blood reviews.

Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis , 9 th ed : Medical Patients : Antithrombotic Therapy Prevention of Thrombosis in Surgical and Approach to Outcome Measurement in the

G. Guyatt, E. Akl, C. Francis, 2012 .

Primary fibrinolysis during supraceliac aortic clamping.

R. Green, J. Deweese, C. Francis, 1997, Journal of vascular surgery.

Physiologic regulation and pathologic disorders of fibrinolysis.

C. Francis, V. Marder, 1987, Human pathology.

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.

C. Francis, R. Brant, M. Mant, 2000, Archives of internal medicine.

Fibrinogen and Fibrin Protect Fibroblast Growth Factor-2 from Proteolytic Degradation

A. Sahni, C. Francis, L. A. Sporn, 2000, Thrombosis and Haemostasis.

Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.

G. Raskob, C. Francis, R. Brant, 2001, Archives of internal medicine.

Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement.

C. Francis, S. Totterman, V. Marder, 1992, JAMA.

Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients.

C. Francis, 2007, The New England journal of medicine.

Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital.

C. Francis, Makiko Ban-hoefen, 2009, Thrombosis research.

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty

C. Francis, S. Berkowitz, J. Lieberman, 2002, Annals of Internal Medicine.

Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding.

C. Francis, V. Marder, C. M. Evarts, 1983, JAMA.

Comparison of Native Prothrombin Antigen With the Prothrombin Time for Monitoring Oral Anticoagulant Prophylaxis

C. Francis, V. Marder, V. Pellegrini, 1993, Circulation.

Embolic complications of calf thrombosis following total hip arthroplasty.

C. Francis, S. Totterman, V. Marder, 1993, The Journal of arthroplasty.

Terminology for fibrinogen γ-chains differing in carboxyl terminal amino acid sequence

C. Francis, M. Mosesson, 1989 .

Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

A. Khorana, C. Francis, G. Connolly, 2013, Clinical lung cancer.

Ximelagatran: a new oral anticoagulant.

C. Francis, 2004, Best practice & research. Clinical haematology.

Enhancement of fibrinolysis with 40-kHz ultrasound.

C. Francis, E. Carstensen, D. Dalecki, 1998, Circulation.

Ultrasound enhancement of fibrinolysis at frequencies of 27 to 100 kHz.

C. Francis, E. Carstensen, V. Suchkova, 2002, Ultrasound in medicine & biology.

Enhancement of fibrinolysis in vitro by ultrasound.

P. T. Onundarson, C. Francis, E. Carstensen, 1992, The Journal of clinical investigation.

Binding of tissue-plasminogen activator to fibrin: effect of ultrasound.

C. Francis, T. Odrljin, P. Fay, 1998, Blood.

Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study.

C. Francis, H. Mieszczanska, S. Messing, 2012, Thrombosis research.

Arthroplastythe Prevention of Venous Thromboembolism After Total Knee Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin

C. Colwell, C. Francis, G. Paiement, 2007 .

Purification and Functional Characterization of Homodimeric yB-yB Fibrinogen From Rat Plasma

C. Francis, P. Fay, T. Wright, 2022 .

15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes.

C. Francis, J. Palis, J. Tober, 2008, Blood.

15-deoxy-12 , 14-PGJ 2 enhances platelet production from megakaryocytes

C. Francis, J. Palis, J. Tober, 2008 .

-PGJ2 enhances platelet production from megakaryocytes

C. Francis, J. Palis, J. Tober, 2008 .

RAPID FORMATION OF LARGE MOLECULAR WEIGHT O-P0LYMERS IN CROSSLINKED FIBRIN INDUCED BY HIGH FACTOR XIII CONCENTRATIONS: ROLE OF PLATELET FACTOR XIII.

C. Francis, V. Marder, Charles W. Francis, 1987, Thrombosis and Haemostasis.

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

C. Francis, B. Eriksson, J. Caprini, 2010, Thrombosis research.

Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42.

C. Francis, M. Hamaguchi, L. A. Sporn, 1993, Blood.

Platelets and Megakaryocytes Contain Functional Nuclear Factor-&kgr;B

C. Francis, M. King, S. Spinelli, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations.

C. Francis, V. Marder, Victor J. Marder, 1988, Blood.

The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.

C. Francis, V. Marder, B. Brenner, 1989, The Journal of laboratory and clinical medicine.

Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.

C. Francis, R. Brant, M. Mant, 2000, Archives of internal medicine.

During warfarin induction, the Fiix‐prothrombin time reflects the anticoagulation level better than the standard prothrombin time

P. T. Onundarson, C. Francis, S. Júlíusson, 2017, Journal of thrombosis and haemostasis : JTH.

Thrombin Activity Associated with Indwelling Central Venous Catheters

C. Francis, A. Felcher, J. Braaten, 1997, Thrombosis and Haemostasis.

Structural studies of fibrinolysis by electron microscopy.

C. Francis, J. Weisel, Y. Veklich, 1998, Blood.

Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences.

T. Foster, C. Francis, R. Bryant, 1990, AJR. American journal of roentgenology.

Concepts of clot lysis.

C. Francis, V. Marder, 1986, Annual review of medicine.

agonists blunt platelet release of CD40 ligand and thromboxanes γ PPAR , and γ Human bone marrow megakaryocytes and platelets express PPAR

C. Francis, N. Blumberg, F. Akbıyık, 2013 .

Effects of ionic and nonionic radiographic contrast agents on endothelial cells in vitro.

C. Francis, V. Marder, M. Owens, 1992, The Journal of laboratory and clinical medicine.

Are Asymptomatic DVTs Relevant?: Response

E. Akl, C. Francis, Y. Falck‐Ytter, 2013 .

Prevention of VTE in patients having major orthopedic surgery

C. Francis, 2013, Journal of Thrombosis and Thrombolysis.

Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.

P. T. Onundarson, C. Francis, V. Marder, 1992, The Journal of laboratory and clinical medicine.

Prophylaxis of venous thrombosis following total hip and total knee replacement using antithrombin III and heparin.

C. Francis, V. Marder, V. Pellegrini, 1991, Seminars in hematology.

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.

A. Khorana, C. Francis, G. Lyman, 2008, Archives of internal medicine.

Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy

A. Khorana, C. Francis, G. Lyman, 2008 .

Degradation of cross-linked fibrin by human leukocyte proteases.

C. Francis, V. Marder, 1986, The Journal of laboratory and clinical medicine.

Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial

A. Khorana, C. Francis, G. Lyman, 2015 .

Demonstration of in situ fibrin degradation in pathologic thrombi.

C. Francis, V. Marder, R. Markham, 1984, Blood.

Comparison of Two Warfarin Regimens in the Prevention of Venous Thrombosis following Total Knee Replacement

C. Francis, S. Totterman, V. Marder, 1996, Thrombosis and Haemostasis.

Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time.

P. T. Onundarson, C. Francis, B. Gudmundsdottir, 2012, Thrombosis research.

Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3.

A. Sahni, C. Francis, Abha Sahni, 2004, Blood.

Preventing VTE in Outpatients With Cancer.

A. Khorana, C. Francis, G. Lyman, 2012, Chest.

Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes.

C. Francis, N. Blumberg, R. Phipps, 2004, Blood.

Venous thromboembolism in patients with diffuse large B-cell lymphoma

R. Fisher, A. Khorana, C. Francis, 2006, Leukemia & lymphoma.

Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments.

C. Francis, J. Weisel, V. Marder, 1993, The Journal of biological chemistry.

Physiological Balance of Haemostasis and Bleeding

C. Francis, V. Marder, 2012, Drugs.

gamma B fibrinogen from rat plasma Purification and functional characterization of homodimeric gamma B

C. Francis, P. Fay, T. Wright, 2011 .

Monitoring of Therapy for Deep Vein Thrombosis Using Magnetic Resonance Imaging

T. Foster, C. Francis, R. Bryant, 1989, Acta radiologica.

Rapid Formation of Large Molecular Weight a-Polymers in Cross-Linked Fibrin Induced by High Factor XIII Concentrations

C. Francis, V. Marder, 1987 .

Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers.

C. Francis, V. Marder, B. Brenner, 1989, Circulation.

Markers of Hemostatic Activation in Affected Coronary Arteries during Angioplasty

C. Francis, M. Cunningham, R. Pomerantz, 1994, Thrombosis and Haemostasis.

Fiix‐prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix‐warfarin or direct oral anticoagulants to standard PT‐warfarin

P. T. Onundarson, D. Arnar, C. Francis, 2016, International journal of laboratory hematology.

Collaborative clinical trials.

A. Moss, C. Francis, D. Ryan, 2011, The New England journal of medicine.

Thrombolysis , Reperfusion and Survival After Myocardial Infarcts Low-Dose Dobutamine Echocardiography Detects Reversible Dysfunction After Thrombolytic Therapy of Acute Myocardial Infarction

C. O'connor, J. Bronzwaer, C. Granger, 2005 .

Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis.

C. Francis, J. Sloand, R. L. Mehta, 1990, The American journal of medicine.

Structural Studies of Fibrinolysis by Electron and Light Microscopy

C. Francis, J. Weisel, J. Collet, 1999, Thrombosis and Haemostasis.

Role of Soluble Crosslinked Fibrin Polymers

C. Francis, V. Marder, B. Brenner, 2005 .

Fibrinogen‐ and Fibrin‐Degradation Products during Fibrinolytic Therapy a

C. Francis, Abraham Kornberg, 1992, Annals of the New York Academy of Sciences.

INCREASED PLASMA CONCENTRATION OF CROSSLINKED FIBRIN POLYMERS IN ACUTE MYOCARDIAL INFARCTION

C. Francis, V. Marder, D. Connaghan, 1987, Thrombosis and Haemostasis.

Protein S declines during winter respiratory infections

A. Falsey, C. Francis, W. Hall, 2003, Journal of thrombosis and haemostasis : JTH.

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.

C. Colwell, C. Francis, J. Heit, 2001, Archives of internal medicine.

Ultrasound Increases Flow through Fibrin Gels

C. Francis, A. Blinc, Julie V. Braaten, 1995, Thrombosis and Haemostasis.

Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products.

C. Francis, V. Marder, D. Ryan, 1986, American journal of clinical pathology.

Antithrombin III plus low-dose heparin in prophylaxis of deep vein thrombosis after total hip and total knee replacement

C. Francis, 1990 .

Antithrombin III/low-dose heparin in the prevention of deep-vein thrombosis after total knee arthroplasty. A preliminary report.

C. Francis, S. Totterman, V. Marder, 1989, Clinical orthopaedics and related research.

Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement.

C. Francis, V. Marder, V. Pellegrini, 1989, American Journal of Medicine.

Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin

C. Francis, J. Ribes, 1990 .

Structural studies of the functional heterogeneity of von Willebrand protein polymers

C. Francis, V. Marder, G. Barlow, 1981 .

Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange

C. Francis, E. Geigel, E. J. GEIGEL, 1997, Acta anaesthesiologica Scandinavica.

Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution.

P. T. Onundarson, C. Francis, J. Rowe, 1992, Archives of internal medicine.

American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.

G. Raskob, C. Flowers, M. Somerfield, 2007, Journal of oncology practice.

A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia.

R. Green, J. Deweese, C. Francis, 1994, Journal of vascular surgery.

Thrombolytic therapy for arterial thrombosis.

C. Francis, C. Shortell, 1999, Current opinion in hematology.

Ultrasound enhancement of rabbit femoral artery thrombolysis.

C. Francis, D. Penney, P. Riggs, 1997, Cardiovascular surgery.

Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty.

J. Ricotta, C. Francis, V. Marder, 1988, Clinical orthopaedics and related research.

Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes.

C. Francis, V. Marder, S. E. Martin, 1980, Blood.

Binding of Tissue-Plasminogen Activator to Fibrin: Effect of Ultrasound

C. Francis, T. Odrljin, P. Fay, 1998 .

15‐deoxy‐Δ12,14 prostaglandin J2‐induced heme oxygenase‐1 in megakaryocytes regulates thrombopoiesis

C. Francis, C. Baglole, N. Blumberg, 2009, Journal of thrombosis and haemostasis : JTH.

Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length.

C. Francis, V. Marder, E. Peerschke, 1986, Blood.

Plasmic degradation of fibrin rapidly decreases platelet adhesion and spreading.

C. Francis, M. Hamaguchi, L. A. Sporn, 1994, Blood.

Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders.

C. Francis, V. Marder, A. Kornberg, 1992, Blood.

ABO‐immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non‐identical transfusion

C. Francis, N. Blumberg, M. Refaai, 2016, Vox sanguinis.

Endothelial cell activation by IL-1beta in the presence of fibrinogen requires alphavbeta3.

A. Sahni, C. Francis, S. Sahni, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Thrombotic thrombocytopenic purpura: Recovery after splenectomy associated with persistence of abnormally large von willebrand factor multimers

C. Francis, V. Marder, J. Rowe, 2006, American journal of hematology.

Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy

A. Khorana, C. Francis, G. Lyman, 2008 .

Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin’s Lymphoma.

R. Fisher, A. Khorana, C. Francis, 2004 .

Management of concomitant factor VII deficiency and Factor V Leiden mutation

C. Francis, M. Refaai, D. Agostini-Vulaj, 2017, International journal of laboratory hematology.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

C. Flowers, A. Khorana, C. Francis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peroxisome proliferator-activated receptor γ and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles

C. Francis, T. Murant, S. Spinelli, 2007, Thrombosis and Haemostasis.

Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment.

C. Francis, V. Marder, S. E. Martin, 1983, Thrombosis Research.

On The Conversion Of High Molecular Weight Urokinase To The Low Molecular Weight Form

C. Francis, V. Marder, G. Barlow, 1981, Thrombosis and Haemostasis.

Secretion of plasminogen activator by the human macrophage‐like cell line, GCT: separation from colony‐stimulating and erythropoiesis‐enhancing activities

C. Francis, A. Lichtman, C. Abboud, 1982, British Journal of Haematology.

On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin.

C. Francis, V. Marder, G. Barlow, 1981, Thrombosis Research.

Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40.

C. Francis, S. Totterman, V. Marder, 1989, The Journal of bone and joint surgery. American volume.

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Yngve Falck-Ytter, Clifford W Colwell, Stephen G Pauker, 2012, Chest.

Evaluation of mild bleeding disorders and easy bruising.

C. Francis, R. Sham, Charles W. Francis, 1994, Blood reviews.

Challenges of rare disease research: limited patients and competing priorities

C. Francis, N. Key, P. Kouides, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain.

C. Francis, D. Wagner, F. Ni, 1989, The Journal of clinical investigation.

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

C. Francis, T. Ortel, N. Kuderer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor‐2 (FGF‐2)

A. Sahni, C. Francis, P. Simpson‐Haidaris, 2007, Journal of thrombosis and haemostasis : JTH.

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

F. Dentali, H. Schünemann, J. Brożek, 2019, Blood advances.

Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.

A. Khorana, C. Francis, G. Lyman, 2010, Thrombosis research.

Interleukin-1␤ but Not Il-1␣ Binds to Fibrinogen and Fibrin and Has Enhanced Activity in the Bound Form Materials and Methods

A. Sahni, C. Francis, M. Guo, 2022 .

The platelet as an immune cell—CD40 ligand and transfusion immunomodulation

Neil Blumberg, Richard P Phipps, C. Francis, 2009, Immunologic research.

Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation.

A. Sahni, C. Francis, C. Francis, 2000, Blood.

Interleukin-1 (cid:1) but not IL-1 (cid:2) binds to ﬁbrinogen and ﬁbrin and has enhanced activity in the bound form

A. Sahni, C. Francis, S. Sahni, 2004 .

Tissue Factor and VEGF Expression in Prostate Carcinoma: A Tissue Microarray Study

A. Khorana, C. Francis, M. Kohli, 2009, Cancer investigation.

Development and validation of a predictive model for chemotherapy-associated thrombosis.

Gary H Lyman, A. Khorana, C. Francis, 2008, Blood.

Plasmic degradation modulates activity of fibrinogen‐bound fibroblast growth factor‐2

A. Sahni, C. Francis, C. Francis, 2003, Journal of thrombosis and haemostasis : JTH.

Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer

Ralph H. Hruban, Galen Hostetter, G. Hostetter, 2007, Clinical Cancer Research.

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

C. Flowers, A. Khorana, C. Francis, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NF-kappaB activation suppresses host cell apoptosis during Rickettsia rickettsii infection via regulatory effects on intracellular localization or levels of apoptogenic and anti-apoptotic proteins.

C. Francis, S. Joshi, S. Sahni, 2004, FEMS microbiology letters.

Low-molecular-weight heparin prophylaxis using dalteparin Extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients : A double-blind, randomized comparison

C. Francis, R. Brant, M. Mant, 2000 .

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients : A double-blind, randomized comparison

C. Francis, R. Brant, M. Mant, 2000 .

Low-molecular-weight heparin prophylaxis using dalteparin Extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients : A double-blind, randomized comparison

C. Francis, R. Brant, M. Mant, 2000 .

Platelet proteome changes associated with diabetes and during platelet storage for transfusion.

C. Francis, L. Paša-Tolić, J. Miller, 2009, Journal of proteome research.

Detection of circulating crosslinked fibrin derivatives by a heat extraction-SDS gradient gel electrophoretic technique.

C. Francis, V. Marder, S. E. Martin, 1979, Blood.

Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.

C. Francis, V. Marder, D. Lane, 1985, Blood.

Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen.

C. Francis, V. Marder, E. Keele, 1984, Biochimica et biophysica acta.

Plasma and Platelet Fibrinogen Differ in γ Chain Content

C. Francis, V. Marder, R. Nachman, 1984, Thrombosis and Haemostasis.

Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights.

C. Francis, V. Marder, D. Kraus, 1983, Biochimica et biophysica acta.

Enzymatic Degradation of the Factor VIII-Von Willebrand Protein:A Unique Tryptic Fragment with Ristocetin Co-Factor Activity

C. Francis, V. Marder, G. Barlow, 1980, Thrombosis and Haemostasis.

Thrombin activity of fibrin thrombi and soluble plasmic derivatives.

C. Francis, V. Marder, G. Barlow, 1983, The Journal of laboratory and clinical medicine.

Calcium modulates plasmin cleavage of the fibrinogen D fragment γ chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the γ chain

C. Francis, T. Odrljin, M. Hamaguchi, 1996 .

Identification of a binding site on human FGF-2 for fibrinogen.

A. Sahni, C. Francis, Hu Peng, 2004, Blood.

Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides.

C. Francis, V. Marder, F. Collichio, 1989, Blood.

Carboxyl-terminal amino acid sequences of two variant forms of the gamma chain of human plasma fibrinogen.

C. Francis, V. Marder, A. Henschen, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen.

C. Francis, V. Marder, S. E. Martin, 1980, The Journal of biological chemistry.

Reactivity of Soluble Fibrin Assays with Plasmic Degradation Products of Fibrin and in Patients Receiving Fibrinolytic Therapy

C. Francis, V. Marder, Bonnie McCarron, 1999, Thrombosis and Haemostasis.

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Gary H Lyman, Christopher R Flowers, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain.

C. Francis, L. Sporn, L. A. Bunce, 1992, The Journal of clinical investigation.

LOWER RISK OF THROMBOEMBOLIC DISEASE AFTER TOTAL HIP REPLACEMENT WITH NON-CEMENTED THAN WITH CEMENTED PROSTHESES

C. Francis, V. Marder, C. M. Evarts, 1986, The Lancet.

Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes

C. Francis, N. Blumberg, R. Phipps, 2004 .

Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran.

C. Francis, S. Totterman, V. Marder, 1990, The Journal of bone and joint surgery. American volume.

Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots.

C. Francis, C W Francis, A. Blinc, 1995, Ultrasound in medicine & biology.

Platelet Activation Following Exposure to Anti-ABO Antibodies-An In Vitro Study.

C. Francis, S. Spinelli, N. Blumberg, 2011, US oncology & hematology.

Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial.

P. T. Onundarson, D. Arnar, C. Francis, 2015, The Lancet. Haematology.

Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3

A. Sahni, C. Francis, 2004 .

New issues in oral anticoagulants.

C. Francis, 2008, Hematology. American Society of Hematology. Education Program.

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Gary H Lyman, Mohammad Jahanzeb, David Trent, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heparin-Binding Domain of Fibrin Mediates Its Binding to Endothelial Cells

C. Francis, T. Odrljin, V. Marder, 1996 .

Heparin-binding domain of fibrin mediates its binding to endothelial cells.

C. Francis, T. Odrljin, V. Marder, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy.

C. Francis, D. Shrier, D. Herrmann, 2002, Neurology.

The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin.

C. Francis, V. Marder, E. Peerschke, 1989, Blood.

Fibrinogen regulates the expression of inflammatory chemokines through NF-κB activation of endothelial cells

A. Sahni, C. Francis, Abha Sahni, 2004, Thrombosis and Haemostasis.

Fibrinolytic therapy for venous thrombosis.

C. Francis, V. Marder, Victor J. Marder, 1991, Progress in cardiovascular diseases.

INCREASED PLASMA CONCENTRATION OF CROSSLINKED FIBRIN POLYMERS IN ACUTE MYOCARDIAL INFARCTION

C. Francis, V. Marder, D. Connaghan, 1987, Thrombosis and Haemostasis.

Dose-Ranging Studies of Anisoylated Plasminogen Streptokinase Activator Complex

C. Francis, V. Marder, R. Rothbard, 2012, Drugs.

Relation of plasma D-dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction.

C. Francis, V. Marder, J. Anderson, 1989, The American journal of cardiology.

Ultrasound accelerates urokinase-induced thrombolysis and reperfusion.

R S Meltzer, C. Francis, R. Meltzer, 1994, American heart journal.

Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz.

C. Francis, E. Everbach, C W Francis, 2000, Ultrasound in medicine & biology.

Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation.

C. Francis, S. Totterman, V. Marder, 1990, Circulation.

Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous.

C. Francis, V. Marder, Charles W. Francis, 1984, The American journal of medicine.

The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands.

C. Francis, S. Spinelli, N. Blumberg, 2007, Prostaglandins & other lipid mediators.

FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis.

A. Khorana, A. Sahni, C. Francis, 2006, Blood.

Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non‐diabetic patients with coronary artery disease

C. Francis, H. Mieszczanska, J. Gerich, 2007, Journal of thrombosis and haemostasis : JTH.

Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.

C. Colwell, C. Francis, G. Paiement, 2005, The Journal of bone and joint surgery. American volume.

Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosis.

Ronald H Gottlieb, Nancy Carson, Deborah J Rubens, 2003, AJR. American journal of roentgenology.

Thromboembolism in hospitalized neutropenic cancer patients.

R. Fisher, A. Khorana, C. Francis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro

C. Francis, S. Spinelli, N. Blumberg, 2014, Transfusion.

Prolonged remission after life‐threatening gastrointestinal hemorrhage from coexistent angiodysplasia and acquired bleeding diathesis

C. Francis, V. Marder, J. Rowe, 1988, American journal of hematology.

A meta-analysis of anticoagulants as cancer treatment: Impact on survival and bleeding complications

A. Khorana, C. Francis, G. Lyman, 2007 .

Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial

P. T. Onundarson, D. Arnar, C. Francis, 2017, Journal of Thrombosis and Thrombolysis.

Two-step warfarin therapy for the prophylaxis of venous thrombosis after elective surgery.

C. Francis, V. Mader, 1987, Advances in experimental medicine and biology.

Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

A. Khorana, C. Francis, G. Lyman, 2009 .

Effect of acoustic cavitation on platelets in the presence of an echo-contrast agent.

C. Francis, E. Everbach, R. Meltzer, 1998, Ultrasound in Medicine and Biology.

A Predictive Risk Score for Cancer-Associated Thrombosis: Role of Screening In A Prospective Study

D. Rubens, A. Khorana, C. Francis, 2010 .

Screening high-risk cancer patients for VTE: a prospective observational study.

D. Rubens, A. Khorana, C. Francis, 2014, Thrombosis research.

Ultrasound and thrombolysis

C. Francis, V. Suchkova, C W Francis, 2001, Vascular medicine.

Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain.

C. Francis, T. Odrljin, M. Hamaguchi, 1996, Biochimica et biophysica acta.

Risk Score For Venous Thromboembolism (VTE) In Ambulatory Patients: Impact Of Cancer Type and Risk Score On VTE Incidence, Early Mortality and Progression-Free Survival

A. Khorana, C. Francis, G. Lyman, 2013 .

Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients

A. Khorana, C. Francis, G. Lyman, 2008 .

Angioedema during therapy with recombinant tissue plasminogen activator.

B. Brenner, C. Francis, V. Marder, 1991, British journal of haematology.

Ultrasound Enhancement of Rabbit Femoral Artery Thrombolysis

C. Francis, D. Penney, P. Riggs, 1997 .

Interleukin-1beta but not IL-1alpha binds to fibrinogen and fibrin and has enhanced activity in the bound form.

A. Sahni, C. Francis, M. Guo, 2004, Blood.

Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction.

A. Moss, C. Francis, W. Zareba, 2005, The American journal of cardiology.

A prediction model for chemotherapy-associated thrombocytopenia in cancer patients.

C. Francis, G. Lyman, J. Crawford, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy.

A. Khorana, C. Francis, G. Lyman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response of C-reactive protein and serum amyloid A to influenza A infection in older adults.

E. Walsh, A. Falsey, C. Francis, 2001, The Journal of infectious diseases.

PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System

C. Francis, P. Declerck, J. Jespersen, 2000, EJIFCC.

Structural Studies On The Functional Heterogeneity Of Von Willebrand Protein Polymers

C. Francis, V. Marder, G. Barlow, 1981 .

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Jason C. Fish, G. Guyatt, S. Vesely, 2012, Chest.

Factor XIII polymorphisms and venous thromboembolism.

C. Francis, 2002, Archives of pathology & laboratory medicine.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

C. Flowers, A. Khorana, C. Francis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Foxp3 Regulates Megakaryopoiesis and Platelet Function

C. Francis, A. Koniski, J. Palis, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

G. Raskob, C. Francis, M. Clements, 2009, The Journal of arthroplasty.

A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

A. Khorana, C. Francis, G. Lyman, 2016, The oncologist.

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

C. Francis, T. Ortel, N. Kuderer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients : A double-blind, randomized comparison

C. Francis, R. Brant, M. Mant, 2000 .

Endothelial cell responses to fibrin mediated by FPB cleavage and the amino terminus of the beta chain.

C. Francis, L. Sporn, L. A. Bunce, 1993, Blood cells.

Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3

C. Francis, Abha Sahni, 2004 .

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.

C. Colwell, C. Francis, J. Heit, 2001, Archives of internal medicine.

Comparison of a low molecular weight heparin and warfarin in prevention of deep vein thrombosis after total hip arthroplasty

C. Francis, A. Rosenberg, S. Totterman, 1997 .

Guideline : Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

G. Raskob, C. Flowers, M. Somerfield, 2007 .

Platelets and Megakaryocytes Contain Functional Nuclear Factor-&kgr;B

C. Francis, M. King, S. Spinelli, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Hemolysis in vivo from exposure to pulsed ultrasound.

R S Meltzer, C. Francis, E. Carstensen, 1997, Ultrasound in medicine & biology.

Structural Studies on the Functional Heterogeneity of

C. Francis, V. Marder, G. Barlow, 2016 .